-
Vascular Health and Risk Management
- About Dovepress
Open access peer-reviewed scientific and medical journals.
- Open Access
Dove Medical Press is now a member of the Open Access Initiative
- An Author's Guide
A guide to help authors get their paper published.
- Advocacy
Support Open Access and Dove Press
- Reprints
Promotional Article Monitoring - further details
- Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes
Review
(6850) Total Article Views
Authors: Bernd Richter, Elizabeth Bandeira-Echtler, Karla Bergerhoff, Christian Lerch
Published Date September 2008 Volume 2008:4(4) Pages 753 - 768
DOI: http://dx.doi.org/10.2147/VHRM.S1707
Bernd Richter, Elizabeth Bandeira-Echtler, Karla Bergerhoff, Christian Lerch
Cochrane Metabolic and Endocrine Disorders Group, Department of General Practice, Heinrich-Heine University Duesseldorf, Duesseldorf, Germany
Background: In type 2 diabetes mellitus (T2DM) there is a progressive loss of β-cell function. One new approach yielding promising results is the use of the orally active dipeptidyl peptidase-4 (DPP-4) inhibitors. However, every new compound for T2DM has to prove long-term safety especially on cardiovascular outcomes.
Objectives: Systematic review and meta-analysis of the effects of sitagliptin and vildagliptin therapy on main efficacy parameters and safety.
Selection criteria, data collection, and analysis: Randomized controlled clinical studies of at least 12 weeks’ duration in T2DM.
Results: DPP-4 inhibitors versus placebo showed glycosylated hemoglobin A1c (A1c) improvements of 0.7% versus placebo but not compared to monotherapy with other hypoglycemic agents (0.3% in favor of controls). The overall risk profile of DPP-4 inhibitors was low, however a 34% relative risk increase (95% confidence interval 10% to 64%, P = 0.004) was noted for all-cause infection associated with sitagliptin use. No data on immune function, health-related quality of life and diabetic complications could be extracted.
Conclusions: DPP-4 inhibitors have some theoretical advantages over existing therapies with oral antidiabetic compounds but should currently be restricted to individual patients. Long-term data on cardiovascular outcomes and safety are needed before widespread use of these new agents.
Keywords: DPP-4 inhibitors, sitagliptin, vildagliptin, systematic review, meta-analysis
Post to:
Cannotea Citeulike Del.icio.us Facebook LinkedIn Twitter
Readers of this article also read:
- ACC 2014
We will attend the 2014 American College of Cardiology Scientific Session and Expo (ACC) on March 29-31, 2014. Stop by booth 3217 to talk with us.
- Like us on Facebook
Click the blue link above to become a part of our Facebook community.
- The western diet and lifestyle and diseases of civilization
- Aldosterone and aldosterone receptor antagonists in patients with chronic heart failure
- Everolimus-eluting stents in interventional cardiology
- Transitioning from population to individualized preventive cardiology